Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $297.72M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.25M
Average 3.81M
Returns on capital
Altimmune, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-39.2%
avg 43.3%
ROIC
-35.4%
avg -49.7%
ROA
-31.5%
avg -32.8%
Analysis
ROA is currently the strongest return metric at -31.5% versus its period average of -32.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Scot Roberts | Chief Scientific Officer | USD 683.23K | 67 | — | — |
Gregory L. Weaver | Chief Financial Officer | USD 619.69K | 70 | 73.00K | 0.08% |
Raymond Jordt | Chief Business Officer | USD 578.85K | 53 | — | — |
Christophe Arbet-Engels | Chief Medical Officer | USD 361.36K | 63 | 24.82K | 0.03% |
Jerome Benedict Durso | Chairman, CEO & President | USD 50.94K | 58 | 93.20K | 0.11% |
Luis Sanay | Vice President of Investor Relations | — | — | — | — |
Richard Menziuso | VP, Global Controller & Principal Accounting Officer | — | 51 | — | — |
Tony Blandin | Vice President of Quality & Compliance Management | — | — | — | — |
Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | — | 38 | 11.37K | 0.01% |
Bertrand Georges | Chief Technology Officer | — | — | — | — |
Robin E. Abrams | Chief Legal Officer & Corporate Secretary | — | 62 | — | — |
Linda Richardson | Chief Commercial Officer | — | 62 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 13, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$452,281.91
Sells
0
$0.00
Net Transaction Value
+$452,281.91
Net buying
Most Active
Durso Jerome Benedict
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 13, 26Nov 13, 2026 | Durso Jerome Benedict Direct | Buy | $49.7K$49,694.09 |
| Nov 13, 26Nov 13, 2026 | WEAVER GREGORY L Direct | Buy | $16.2K$16,200.00 |
| Nov 13, 26Nov 13, 2026 | Pisano Wayne Direct | Buy | $16.4K$16,350.00 |
| Aug 13, 26Aug 13, 2026 | Durso Jerome Benedict Direct | Buy | $44.3K$44,250.00 |
| Apr 6, 26Apr 6, 2026 | GILL JOHN Direct | Buy | $31.3K$31,349.92 |
| Apr 1, 26Apr 1, 2026 | WEAVER GREGORY L Direct | Buy | $31.5K$31,499.00 |
| Apr 1, 26Apr 1, 2026 | Durso Jerome Benedict Direct | Buy | $47.1K$47,100.00 |
| Mar 6, 26Mar 6, 2026 | WEAVER GREGORY L Direct | Buy | $17.7K$17,700.00 |
| Mar 6, 26Mar 6, 2026 | Durso Jerome Benedict Direct | Buy | $70.8K$70,790.00 |
| Jan 8, 26Jan 8, 2026 | Pisano Wayne Direct | Buy | $20.4K$20,410.00 |
1–10 of 14
Summary
Insiders reported 14 buys worth $452,281.91 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $452,281.91. Durso Jerome Benedict was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +418.3% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +418.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Altimmune, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ALT's management, answered from reported figures.
Who manages ALT?
Altimmune, Inc. (ALT) lists 12 active executives. The top listed executive is Jerome Benedict Durso, Chairman, CEO & President.
Are ALT insiders buying or selling?
Recent insider activity shows net buying of $29.21M.
Continue the stock analysis
Jump to another research area for this company.